




EY Entrepreneur of the year-2013



FROST & SULLIVAN 2013 Best Practices-2013



Business today/YES bank Excellence Awards-2013



Date: 29th July, 2021

To BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
Security Code: 540596	Symbol: ERIS

SUBJECT: INTIMATION IN TERMS OF REGULATION 30 READ WITH SCHEDULE III PART A (1)

Dear Sir / Madam,

An intimation in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Schedule III Part A(1), read with SEBI Circular CIR/CFD/CMD/4/2015 September 09, 2015 is attached as 'Annexure A' .

You are requested to take the above information on record.

Thanking You,
Yours faithfully,
Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary and Compliance Officer

DISCLOSURE IN TERMS OF REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 READ WITH SEBI CIRCULAR CIR/CFD/CMD/4/2015 SEPTEMBER 09, 2015 ARE AS UNDER:

Sr. No.	Details of events	Disclosure
1	Name of the target entity, details in brief such as size, turnover etc.	<p>Eris Therapeutics Limited ("Eris Therapeutics")</p> <p>Authorized Share Capital: 1,00,000/- Paid-up Share Capital: 1,00,000/-</p> <p>Turnover: Nil (newly incorporated, hence yet to commence its business operations)</p>
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length"	<p>The action would not fall within related party transaction(s).</p> <p>None of the promoter/ promoter group/ group companies have any interest in the entity being acquired.</p>
3	Industry to which the entity being acquired belongs	Pharmaceuticals
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	<p>Object: Company considers it prudent to maximize in-house production with a view to retain optimal control on quality, supply and cost. As per our estimates, the capacity utilization of the main tablets block at our existing plant at Guwahati will near 80% in the next 3 financial years. It, therefore, becomes imperative for the company to commence a Greenfield project for the setting up of a formulations manufacturing facility which could be expected to be commissioned before the end of the financial year 2023 and that is built and operated on WHO GMP standards. The new facility is to be developed by the wholly owned subsidiary 'Eris Therapeutics' at Gujarat.</p> <p>Effects: Mitigation of the risks arising from a single location manufacturing operation. Augmentation of the existing manufacturing capacity. The new facility shall have the ability to manufacture new dosage forms like sterile injectables (ampoules, lyophilized, pre-filled syringes) and oral liquids. Moreover, the new facility shall also</p>

		have a Formulation R&D block including Analytical & Microbiology labs.
5	Brief details of any governmental or regulatory approvals required for the acquisition	NA
6	Indicative time period for completion of the acquisition	NA
7	Nature of consideration - whether cash consideration or share swap and details of the same	NA
8	Cost of acquisition or the price at which the shares are acquired	Rs. 1,00,000/- (10,000 Equity shares of Rs. 10/- each)
9	Percentage of shareholding / control acquired and / or number of shares acquired	The Company together with its nominees shall hold the entire share capital of Eris Therapeutics
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Date of Incorporation: 23-06-2021 History of last 3 years: Not Applicable Country: India. Also refer para 4 above.
11.	Capacity addition or product launch	
11.1	Capacity addition	(Group level)
(a)	Existing capacity	Ref: https://eris.co.in/supply-chain/
(b)	Existing capacity utilization	60% in the main tablets block
(c)	proposed capacity addition	It will evolve over time as per business dynamics
(d)	period within which the proposed capacity is to be added	5 years
(e)	investment required;	INR 130 crore in the first phase
(f)	mode of financing	Internal accruals
(g)	rationale	The measure would augment the existing in-house manufacturing capabilities and capacities of the Group.

Eris Lifesciences Limited

Milind Talegaonkar

Company Secretary and Compliance Officer